ArticleEuropean radiology experimental2026
Dual-energy CT biomarkers for predicting the efficacy of TACE combined with lenvatinib and immune checkpoint inhibitors in unresectable HCC.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo develop a nomogram based on low-dose one-stop dual-energy and perfusion computed tomography (LD-DE&PCT) for predicting the efficacy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and immune checkpoint inhibitors (TACE-LEN-ICIs) in unresectable hepatocellular carcinoma (uHCC) patients. MATERIALS AND
methodsThis prospective, multicenter study included uHCC patients who underwent LD-DE&PCT scanning. The relationships between quantitative LD-DE&PCT-derived parameters and the efficacy of TACE-LEN-ICIs were analyzed using logistic regression analysis. A nomogram incorporating the independent predictors was constructed, and its predictive performance was evaluated by the area under the receiver operating characteristic curve (AUROC).
resultsA total of 125 lesions from 71 uHCC patients were enrolled, with 71 lesions (56.8%) classified as the objective response (ObR) group and 54 lesions (43.2%) as the non-response (NR) group. Univariate analysis revealed significant differences in tumor size, corona enhancement, tumor location, iodine concentration in the arterial phase (IC-AP), normalized iodine concentration in the arterial phase (NIC-AP), effective atomic number in the arterial phase (Z
conclusionThe LD-DE&PCT-based nomogram can accurately predict the response to TACE-LEN-ICIs in uHCC patients. RELEVANCE STATEMENT: Low-dose one-stop dual-energy and perfusion CT provides a noninvasive method to predict response to TACE combined with lenvatinib and immune checkpoint inhibitors in unresectable HCC. KEY POINTS: Predicting response to TACE-LEN-ICIs in uHCC helps treatment decision-making. NIC-AP and PS from LD-DE&PCT, and tumor size were independent predictive biomarkers. NIC-AP was the best parameter for predicting response to TACE-LEN-ICIs in uHCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.